Pharma executive Martin Shkreli is out at another biotech firm, a few days after he defiantly called his arrest last week for fraud completely baseless.
The tiny biotech KaloBios announced Monday that Shkreli was fired from the position of CEO and he resigned from his seat on the board of directors. The move comes a few days after Shkreli resigned from being CEO at Turing Pharmaceuticals, where he infamously raised the price of a decades-old drug by 5,000 percent.
Shkreli had been CEO of KaloBios since November when a group of investors led by Shkreli acquired a majority of the company’s shares.
Shkreli faces seven counts of securities and wire fraud and was arrested by the FBI last week.
The charges, which Shkreli has pled not guilty to, aren’t related to Turing’s price hike of Daraprim, a treatment for the parasitic condition called toxoplasmosis. The drug’s price skyrocketed from $13.50 to $750 a pill almost overnight after Turing acquired it in August.
Shkreli, a prolific Twitter user whose social media antics fueled public anger against him, tweeted last week that the allegations against him were baseless and without merit.
On Sunday, the always controversial Shkreli tweeted, “I am now a God.”
